HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aleve Sinus & Headache NDA

This article was originally published in The Tan Sheet

Executive Summary

Labeling supplement (NDA 21-076/S7) for naproxen sodium 220 mg/extended-release pseudoephedrine 120 mg combination approved by FDA July 31. Bayer says agency asked it to file formal supplement to add the Sinus & Headache sub-brand under previously approved NDA for Aleve Cold & Sinus; both products contain the same formulation. Sinus & Headache began shipping in July 2001 (1"The Tan Sheet" July 9, 2001, p. 3)...

You may also be interested in...



Bayer Alka-Seltzer Morning Relief Eases Hangover Headaches, Fatigue

Alka-Seltzer Morning Relief will be the first OTC product "specifically indicated to relieve morning headache and fatigue associated with a hangover," Bayer Consumer Care claimed.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel